Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Date of Graduation
Objective: Does the use of polypill therapy improve systolic blood pressure and low-density lipoprotein cholesterol (LDL-C) levels more than usual care in adults with established cardiovascular disease (CVD) or with 10-year atherosclerotic cardiovascular disease risk >10%. Design: Systematic literature review. Methods: Searches were performed in PubMed and UpToDate using the following search terms polypill and cardiovascular. Other limits included: randomized control trials, adults, published in the last 10 years, LDL-C and systolic blood pressure. Results: Analysis of articles to ensure similar design, intervention and fit with the other inclusion/exclusion criteria yielded three studies: Labefer et al, Muñoz et al, and Patel et al. 9,10,11 Conclusion: The polypill should be considered in all adults who have a 10-year ASCVD event risk >10% or those previously diagnosed with CVD. The polypill should particularly be considered in subgroups such as those taking fewer than two anti-hypertensive medications, patients who are failing to meet cholesterol goals with low potency statins or individuals that face challenges accessing medications. Price and production of the polypill in the United States remains to be seen and would have a significant impact on the clinical power of the polypill.
Voytovich A, McKee C. Are Polypills a Viable Option to Improve Health Outcomes in Those with Cardiovascular Disease? 2021